Neurocrine Biosciences Begins Phase 1 Trial for NBI-1140675 in Neurological Disorders

Neurocrine Biosciences, Inc. announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynami...

March 06, 2025 | Thursday | News
FDA Accepts Roche’s sBLA for Gazyva®/Gazyvaro® (Obinutuzumab) as a Treatment for Lupus Nephritis

Roche announced  that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for...

March 06, 2025 | Thursday | News
Roche Reports Positive Phase III OUtMATCH Data, Strengthening Xolair® for Food Allergies

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide fur...

March 06, 2025 | Thursday | News
Celon Pharma Announces Positive Phase 2 Results for CPL’36 in Treating Levodopa-Induced Dyskinesia in Parkinson's Disease

Celon Pharma S.A.  announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily med...

March 05, 2025 | Wednesday | News
GHIT Fund Marks Milestone with First Administration of Arpraziquantel to Preschool Children in Uganda

The Global Health Innovative Technology (GHIT) Fund is announcing a significant milestone: the first administration of arpraziquantel to preschool-aged chi...

March 05, 2025 | Wednesday | News
Advancements in Tenosynovial Giant Cell Tumor Treatment with Surgery and Targeted Therapies

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...

March 05, 2025 | Wednesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News
Jasper Therapeutics Presents Promising Updated Data on Briquilimab for Mast Cell-Driven Diseases at AAAAI 2025

Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...

March 03, 2025 | Monday | News
GSK Announces Positive Phase III Results for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus pl...

March 03, 2025 | Monday | News
Amgen and AstraZeneca's TEZSPIRE® Demonstrates Significant Efficacy in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Amgen and AstraZeneca announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) signi...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News
Myriad Genetics Partners with Gabbi to Enhance Breast Cancer Risk Assessment and Specialist Care

Myriad Genetics, Inc., a leader in molecular diagnostics testing and precision medicine, announced a collaboration with Gabbi, a telehealth solution f...

February 28, 2025 | Friday | News
Alumis to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025

Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...

February 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close